These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28370072)

  • 1. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
    Salih MAM; Fakiola M; Lyons PA; Younis BM; Musa AM; Elhassan AM; Anderson D; Syn G; Ibrahim ME; Blackwell JM; Mohamed HS
    Parasite Immunol; 2017 Jun; 39(6):. PubMed ID: 28370072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
    Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
    Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis.
    Elshafie AI; Ahlin E; Mathsson L; ElGhazali G; Rönnelid J
    J Immunol; 2007 Apr; 178(8):5383-9. PubMed ID: 17404324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
    Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
    Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
    Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment.
    el Hassan AM; Ghalib HW; Zijlstra EE; Eltoum IA; Satti M; Ali MS; Ali HM
    Trans R Soc Trop Med Hyg; 1992; 86(3):245-8. PubMed ID: 1329273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
    Veeken H; Ritmeijer K; Seaman J; Davidson R
    Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
    Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.
    Salih MA; Fakiola M; Abdelraheem MH; Younis BM; Musa AM; ElHassan AM; Blackwell JM; Ibrahim ME; Mohamed HS
    BMC Infect Dis; 2014 Dec; 14():662. PubMed ID: 25466928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A; Singh N; Sundar S; Singh N
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
    Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
    Ramesh V; Kumar J; Kumar D; Salotra P
    Indian J Dermatol Venereol Leprol; 2010; 76(2):138-44. PubMed ID: 20228542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1.
    Dhar S; Kaur I; Dawn G; Sehgal S; Kumar B
    Lepr Rev; 1995 Sep; 66(3):250-6. PubMed ID: 7500822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
    Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.